MPLT: Fails ASD Trial
MapLight Therapeutics' IRIS A Phase 2 study of ML-004 in Autism Spectrum Disorder did not meet its primary endpoint
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.